Nilotinib-Associated Destructive Thyroiditis

Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several si...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in endocrinology 2015-01, Vol.2015 (2015), p.1-3
Main Authors: Valiquette, Guy, Goldberg, Michael D., Schwarcz, Monica D., Bakerywala, Suhalia, Weiss, Irene A.
Format: Article
Language:English
Subjects:
Apoptosis
Binding sites
Cardiac arrhythmia
Case Report
Cyclin-dependent kinases
Enzymes
Epidermal growth factor
Hospitals
Hypothyroidism
Kinases
Laboratories
Older people
Patients
Thyroid cancer
Vascular endothelial growth factor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Protein tyrosine kinase inhibitors are currently an important drug class in the treatment of leukemia. They represent targeted cancer therapy and have become the treatment of choice in chronic myeloid leukemia. Tyrosine kinases are enzymes expressed in multiple tissues and are involved in several signaling pathways influencing cellular growth. Below we describe a patient who developed an unusual complication of tyrosine kinase inhibitor therapy: thyrotoxicosis due to destructive thyroiditis. We review the pathophysiology of tyrosine kinase inhibitor-induced thyroid dysfunction particularly with regard to new second-generation tyrosine kinase inhibitors.
ISSN:2090-6501
2090-651X
DOI:10.1155/2015/736092